Liu Q, Garner P, Wang Y, Huang B, Smith H
Product Form and Specification IGF-1 LR3 is supplied as a white lyophilized powder in sterile, sealed vials
Furthermore, the risks of myocardial infarction (HR 0.91, 95% CI 0.840.98 with GLP-1RAs and HR 0.89, 95% CI 0.800.98 with SGLT2is) and cardiovascular death (HR 0.88, 95% CI 0.800.96 with GLP-1RAs and HR 0.84, 95% CI 0.750.94 with SGLT2is) were similarly reduced in both GLP-1RA and SGLT2i groups, while the risk of stroke was reduced only with GLP-1RAs (HR 0.86, 95% CI 0.770.97 with GLP-1RAs and HR 0.97, 95% CI 0.861.10 with SGLT2is)
The addition of supportive compounds to tirzepatide is another area of active exploration
BPC-157 is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems